[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100395711":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":46,"collaborators":21,"id":50,"slug":21,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":21,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":21,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":21,"overallStatus":31,"whyStopped":21,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Effectiveness of 4SCAR-276 T cells","EXPERIMENTAL","The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors",[13],"Biological: 4SCAR-276",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","4SCAR-276",[9],[20],"CD276-specific 4th Generation CART",null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Lung-Ji Chang, Ph.D","CONTACT","+86-13671121909","c@szgimi.org",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Shenzhen Geno-immune Medical Institute","RECRUITING","Shenzhen","Guangdong","518000","China",{"type":37,"coordinates":38},"Point",[39,40],114.0683,22.54554,{"lat":40,"lon":39},[43],{"name":44,"role":25,"phone":45,"phoneExt":21,"email":27},"Lung-Ji Chang, PhD","+86 0755-86573763",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Lung-Ji Chang","President","100395711",false,"NCT04432649","Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276","Multicenter Trial of Phase I\u002FII Studies on CD276 (B7-H3) Positive Solid Tumors Treated With 4SCAR-276","Inclusion Criteria:\n\n* Patients with tumors have received standard first-line therapy and have been judged to be non-resectable, metastatic, progressive or recurrent.\n* The CD276 antigen status of the tumor is determined for eligibility. Positive expression is defined by antibody staining results based on immunohistochemistry or flow cytometry analysis.\n* Body weight greater than or equal to 10 kg.\n* Age: ≥1 year and ≤ 75 years of age at the time of enrollment.\n* Life expectancy: at least 8 weeks.\n* Prior Therapy: 1) There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less. 2) Must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection. 3) At least 7 days must have elapsed since the completion of therapy with a biologic agent, targeted agent, tyrosine kinase inhibitor or a metronomic nonmyelosuppressive regimen. 4) At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody. 5) At least 1 week since any radiation therapy at the time of study entry.\n* Karnofsky\u002Fjansky score of 60% or greater.\n* Cardiac function: Left ventricular ejection fraction greater than or equal to 40\u002F55 percent .\n* Pulse Ox greater than or equal to 90% on room air.\n* Liver function: defined as alanine transaminase (ALT) \\\u003C3x upper limit of normal (ULN), aspartate aminotransferase (AST) \\\u003C3x ULN; serum bilirubin and alkaline phosphatase \\\u003C2x ULN.\n* Renal function: Patients must have serum creatinine less than 3 times upper limit of normal.\n* Marrow function: White blood cell count ≥1000\u002Ful, Absolute neutrophil count ≥500\u002Ful, Absolute lymphocyte count ≥500\u002Ful, Platelet count ≥25,000\u002Ful (not achieved by transfusion).\n* Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease not evaluable to have hematologic toxicity.\n* For all patients enrolled in this study, themselves or their parents or legal guardians must sign an informed consent and assent.\n\nExclusion Criteria:\n\nExisting severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, or grade 3 hematologic toxicity.\n\n* Untreated central nervous system (CNS) metastasis: Patients with CNS tumor involvement that has been treated and\u002For is stable for at least 6 weeks following completion of therapy are eligible.\n* Previous treatment with other genetically engineered CD276-CAR T cells or CD276 antibody therapy.\n* Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.\n* Patients who require systemic corticosteroid or other immunosuppressive therapy.\n* Evidence of tumor potentially causing airway obstruction.\n* Inability to comply with protocol requirements.\n* Insufficient CAR T cells availability.","ALL","1 Year","75 Years",{"count":60,"type":61},100,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE1","PHASE2","Patients with refractory and\u002For recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. This study attempts to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 domain) targeting CD276 (B7-H3). The 4SCAR-CD276-modified T cells (4SCAR-276) can recognize and kill tumor cells through the recognition of CD276, a surface protein expressed at high levels on many types of tumors but at low levels on normal tissues. This study will evaluate the side effects and effective doses of 4SCAR-276 in treating refractory and\u002For recurrent tumors.",[68],"Solid Tumor","2026-06-18",{"date":71,"type":72},"2026-06-23","ACTUAL",{"date":74,"type":72},"2026-06-01",{"date":76,"type":61},"2030-12-31",{"name":5,"class":6},1]